New triple combo tackles recurrent brain tumors
NCT ID NCT06558214
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tests if combining three treatments—electric field therapy (TTFields), laser ablation surgery, and an immunotherapy drug (pembrolizumab)—is safe and doable for adults with recurrent glioblastoma, an aggressive brain cancer. About 20 participants will receive the combination and be monitored for side effects. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UF Health Shands Hospital
RECRUITINGGainesville, Florida, 32608, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.